Skip Navigation

JNCI Journal of the National Cancer Institute 2005 97(7):542; doi:10.1093/jnci/dji090
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Yalcin, B.
Right arrow Articles by Altan, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yalcin, B.
Right arrow Articles by Altan, M.
Related Collections
Right arrowResponse to this Correspondence
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 Oxford University Press

CORRESPONDENCE

Re: Continuing Outcomes Relevant to Evista: Breast Cancer Incidence in Postmenopausal Osteoporotic Women in a Randomized Trial of Raloxifene

Bulent Yalcin, Abdullah Buyukcelik, Samet Yalcin, Gungor Utkan, Hatice Doruk, Mutlu Dogan, Mehmet Altan

Affiliations of authors: Department of Medical Oncology, Ankara University School of Medicine, Sihhiye, Ankara, Turkey (BY, AB, GU, HD); Department of Internal Medicine (MD, MA) and Department of General Surgery (SY), Ankara University School of Medicine, Sihhiye, Ankara, Turkey

Correspondence to: Bulent Yalcin, MD, Department of Medical Oncology, Ankara University School of Medicine, TR-06100, Sihhiye, Ankara, Turkey (e-mail: bulyalcin@yahoo.com).

The first 10% of the full text of this article appears below.

In their recent article, Martino et al. (1) concluded that raloxifene treatment reduces the incidence of estrogren receptor (ER)–positive invasive breast cancer in postmenopausal women with . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Response to this Correspondence

RESPONSE: Re: Continuing Outcomes Relevant to Evista: Breast Cancer Incidence in Postmenopausal Osteoporotic Women in a Randomized Trial of Raloxifene
Silvana Martino, Jane A. Cauley, Elizabeth Barrett-Connor, Trevor J. Powles, John Mershon, Damon Disch, Roberta J. Secrest, and Steven R. Cummings
J Natl Cancer Inst 2005 97: 542-543. [Extract] [Full Text] [PDF]